Show simple item record

dc.contributor.authorRaijmakers, NJHen_US
dc.contributor.authorZijlstra, Men_US
dc.contributor.authorvan Roij, Jen_US
dc.contributor.authorHusson, Oen_US
dc.contributor.authorOerlemans, Sen_US
dc.contributor.authorvan de Poll-Franse, LVen_US
dc.coverage.spatialGermanyen_US
dc.date.accessioned2019-01-08T10:25:11Z
dc.date.issued2018-10en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29663137en_US
dc.identifier10.1007/s00520-018-4181-6en_US
dc.identifier.citationSupport Care Cancer, 2018, 26 (10), pp. 3397 - 3404en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2996
dc.identifier.eissn1433-7339en_US
dc.identifier.doi10.1007/s00520-018-4181-6en_US
dc.description.abstractPURPOSE: The aim of this study was to assess health-related quality of life (HRQoL) in the last year of life of cancer patients stratified by four periods of time before death. PATIENTS AND METHODS: Between 2008 and 2015, cancer patients were invited to participate in PROFILES (Patient Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship) registry studies. Patients were eligible for inclusion in this secondary analysis if they had been invited to complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in their last year of life (N = 892). Four hundred fifty-eight patients (51%) responded. Descriptive statistics were used to describe the HRQoL of cancer patients in the last 3 months of life (N = 61), the last 3-6 months (N = 110), the last 6-9 months (N = 138), or the last 9-12 months of their life (N = 129). RESULTS: Patients in the last 3 months report a significant lower HRQoL, lower functioning, and higher symptom burden of fatigue and appetite loss compared to patients in different time periods before death (p < 0.008). Clinical relevance of the differences for global QoL, cognitive, and social functioning was large. Patients' HRQoL in the last year of life was significantly lower than that of the normative population (p < 0.001). CONCLUSIONS: All aspects of HRQoL are considerably impaired in patients with advanced cancer, with a marked lower HRQoL in the final months of life. This marked decline of HRQoL in the final months of life may be an indicator of approaching death and serve as an important trigger for end-of-life communication and decision-making about subsequent treatment and supportive care.en_US
dc.format.extent3397 - 3404en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.subjectAdvanced canceren_US
dc.subjectPalliative careen_US
dc.subjectPopulation-based cohorten_US
dc.subjectQuality of lifeen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectNeoplasmsen_US
dc.subjectQuality of Lifeen_US
dc.subjectSurveys and Questionnairesen_US
dc.subjectTerminal Careen_US
dc.titleHealth-related quality of life among cancer patients in their last year of life: results from the PROFILES registry.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-03-23en_US
rioxxterms.versionofrecord10.1007/s00520-018-4181-6en_US
rioxxterms.licenseref.startdate2018-10en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfSupport Care Canceren_US
pubs.issue10en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.publication-statusPublisheden_US
pubs.volume26en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical and Translational Sarcomaen_US
dc.contributor.icrauthorHusson, Olgaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record